èšåºæ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ãã Galectin Therapeutics Inc. ã¯ãç·ç¶çãçãããã³ãã®ä»ã®çŸæ£ã®æ²»çæ³ã®ç ç©¶éçºã«åãçµãã§ããŸããå瀟ã®äž»å補ååè£ã¯ãèèªèçŸæ£ããã³éã¢ã«ã³ãŒã«æ§èèªèçè硬å€ã«äŒŽãèç·ç¶çã®æ²»çããªãã³ã«çã®æ²»çãç®çãšãã第 III çžèšåºè©Šéšäžã®ã¬ã©ã¯ãã¢ã©ãã-ã©ã ãã¬ã©ã¯ãããã³å€ç³é¡ããªããŒã§ãããã©ãã¯ãã³ ã¬ã¬ã¯ãã³ 3 é»å®³å€ (GR-MD-02) ã§ããå瀟ã¯ãŸããå¿èããã³è¡ç®¡ç·ç¶çã®æ²»çãç®çãšããåèšåºéçºæ®µéã«ãã GM-CT-01 ã®éçºã«åãçµãã§ããã也ç¬ãèºããã³è
èç·ç¶çã®æ²»çãç®çãšãããã©ãã¯ãã³ã®éçºã«ã泚åããŠããŸããå瀟ã¯ãSBH Sciences, Inc. ãšå
±åææããå
±åååŒäŒç€Ÿã§ãã Galectin Sciences, LLC ãéããŠãçµå£æäžçšã®ã¬ã¬ã¯ãã³ 3 ã®å°ææ©ååé»å®³å€ã®ç ç©¶éçºãè¡ã£ãŠããŸããå瀟ã¯ä»¥å㯠Pro-Pharmaceuticals, Inc. ãšããŠç¥ãããŠããŸãããã2011 幎 5 æã« Galectin Therapeutics, Inc. ã«ç€Ÿåã倿ŽããŸãããGalectin Therapeutics Inc. 㯠2000 幎ã«èšç«ããããžã§ãŒãžã¢å·ããŒã¯ãã¹ã«æ ç¹ã眮ããŠããŸãã